基于美国FDA不良事件报告系统(FAERS)的阿巴洛肽真实世界药物警戒研究
本研究回顾性挖掘FAERS数据库2017年第二季度至2022年数据,共收集8,470,497份报告,其中11,487份将阿巴洛肽列为主要可疑药物,采用ROR、PRR、BCPNN和MGPS四种算法检测到99个同时符合四种算法的信号,其中35个为非预期信号。患者年龄(p < 0.001)可能与不良事件严重程度风险增加相关,不良事件最常见发生时间为0-7天。
要点
- 共检测到99个同时符合四种算法的阿巴洛肽相关不良事件信号,其中35个为非预期信号。
- 非预期信号包括生长痛(n=13)、腰围增加(n=21)、感觉障碍(n=103)、耳鸣(n=65)、视力下降(n=54)、碱性磷酸酶升高(n=61)和毛发增长异常(n=13)。
- 患者年龄(p < 0.001)可能与不良事件严重程度风险增加相关,不良事件最常见发生时间为0-7天。
核心结论
- 本研究提供了对阿巴洛肽安全性特征更深入和更广泛的了解,有助于医疗专业人员在临床实践中降低不良事件风险,非预期不良事件数量较少,支持继续进行额外的药物警戒。
研究设计与样本
- 回顾性挖掘美国FDA不良事件报告系统(FAERS)数据库,研究时段为2017年第二季度至2022年。
- 共收集8,470,497份FAERS报告,其中11,487份将阿巴洛肽列为主要可疑(PS)药物。
- 采用报告比值比(ROR)、比例报告比(PRR)、贝叶斯置信传播神经网络(BCPNN)和多项目伽马泊松收缩器(MGPS)四种算法量化阿巴洛肽相关不良事件信号。
- 严重与非严重病例采用Mann-Whitney U检验或卡方(χ2)检验进行比较。
主要发现
- 在11,487份以阿巴洛肽为主要可疑药物的报告中,36.16%由医疗专业人员提交(n=4154),62.26%由消费者报告(n=7140)。
- 共检测到99个同时符合四种算法的信号,其中35个被识别为非预期信号。
- 非预期信号包括生长痛(n=13)、腰围增加(n=21)、感觉障碍(n=103)、耳鸣(n=65)、视力下降(n=54)、碱性磷酸酶升高(n=61)和毛发增长异常(n=13)。
- 患者年龄(p < 0.001)可能与不良事件严重程度风险增加相关。
- 不良事件最常见发生时间窗为0-7天。
关键数值与推荐
- 共检测到99个同时符合四种算法的信号,其中35个为非预期信号。
- 患者年龄与不良事件严重程度风险的关联p < 0.001。
- 不良事件最常见发生时间窗为0-7天。
临床怎么用
- 原文结论指出本研究有助于医疗专业人员在临床实践中降低不良事件风险,非预期不良事件数量较少支持继续进行额外的药物警戒。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Abaloparatide (ABL) is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. However, real-world data regarding its long-term safety and tolerability in large sample population are incomplete. We evaluated abaloparatide-associated safety signals by data mining of the FDA pharmacovigilance database. INTRODUCTION: We investigated 33,480(0.14%) ABL-related adverse events (AEs) through data mining of Food and Drug Administration Adverse Event Reporting System (FAERS) retrospectively. METHODS: Reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) were employed to quantify the signals of ABL-related AEs from 2017Quarter2 to 2022.Serious and non-serious cases were compared by Mann-Whitney U test or Chi-squared (χ2) test. RESULTS: We collected 8,470,497 reports from the FAERS database, including 11,487 reports defined ABL as the primary suspected (PS) drug. Additionally, 36.16% of the reports were submitted by healthcare professionals (n=4154), compared to 62.26% reported by consumers (n=7140). A total 99 signals simultaneously conforming to four algorithms were detected, among which, 35 signals were identified as unexpected signals. Such as growing pains (n=13), waist circumference increased (n=21), sensory disturbance (n=103), tinnitus (n=65), visual acuity reduced (n=54), blood alkaline phosphatase increased (n=61), and hair growth abnormal (n=13). Patient age (p < 0.001) might be associated with an increased risk of AEs severity. The most common timeframe for AE occurrence was 0-7 days. CONCLUSION: Our study provided a deeper and broader understanding of abaloparatide's safety profiles, which would help healthcare professionals to mitigate the risk of AEs in clinical practice, a low number of unexpected AEs supporting ongoing additional pharmacovigilance.
引用
- Shi X, Cheng Q, Zhao YZ, et al. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS). Osteoporos Int. 2023. PMID: 37594595. doi:10.1007/s00198-023-06877-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。